Immunome Dirección

Dirección controles de criterios 0/4

El CEO de Immunome's es Clay Siegall, nombrado en Jan 2023, tiene una permanencia de 1.25 años. posee directamente un 0.54% de las acciones de la empresa, con un valor de $4.56M. La antigüedad media del equipo directivo y de la junta directiva es de 0.5 años y 2.8 años, respectivamente.

Información clave

Clay Siegall

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.3yrs
Participación del CEO	0.5%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Clay Siegall (62 yo)

1.3yrs

Permanencia

Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of MorphImmune, Inc. from March 2023 until Octobe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Clay Siegall	President	1.3yrs	sin datos	0.54% $ 4.4m
Max Rosett	Interim CFO & Executive VP of Operations	less than a year	sin datos	0.033% $ 272.6k
Robert Lapetina	Principal Accounting Officer	less than a year	sin datos	0.020% $ 165.4k
Philip Roberts	Chief Technical Officer	less than a year	sin datos	sin datos
Jack Higgins	Chief Scientific Officer	1.3yrs	sin datos	sin datos
Sandra Stoneman	Chief Legal Officer	3.5yrs	US$1.64m	0.0093% $ 76.3k
Bruce Turner	Chief Strategy Officer	1.3yrs	sin datos	0.071% $ 580.8k
Robert Lechleider	Chief Medical Officer	less than a year	sin datos	sin datos
Kinney Horn	Chief Business Officer	less than a year	sin datos	sin datos

0.5yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMNM no se considera experimentado ( 0.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Clay Siegall	President	1.3yrs	sin datos	0.54% $ 4.4m
Louis Weiner	Member of Scientific Advisory Board	no data	sin datos	sin datos
Philip Wagenheim	Director	6.3yrs	US$47.14k	0.68% $ 5.6m
George Prendergast	Member of Scientific Advisory Board	no data	sin datos	sin datos
Isaac Barchas	Lead Independent Director	1.3yrs	sin datos	0.33% $ 2.7m
James Boylan	Director	1.3yrs	sin datos	sin datos
Andrew Badley	Member of COVID-19 Advisory Board	2.8yrs	sin datos	sin datos
Carol Schafer	Director	less than a year	sin datos	sin datos
William Strohl	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Henderson	Member of COVID-19 Advisory Board	3.6yrs	sin datos	sin datos
Shmuel Shoham	Member of COVID-19 Advisory Board	3.6yrs	sin datos	sin datos
Susan Weiss	Member of COVID-19 Advisory Board	3.6yrs	sin datos	sin datos

2.8yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de IMNM no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Immunome Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Recent updates

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares

New 90-day high: US$13.73

Immunome, Inc. Appoints Diane Marcou as Interim Chief Financial Officer

Immunome EPS misses by $7.22

Key Executive recently bought US$1m worth of stock

Immunome, Inc. has completed an IPO in the amount of $39 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad